Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

Blood

Volumn 103, Issue 5, 2004, Pages 1807-1814

  DiJoseph, John F ^b   Armellino, Douglas C ^b   Boghaert, Erwin R ^b   Khandke, Kiran ^b   Dougher, Maureen M ^b   Sridharan, Latha ^b   Kunz, Arthur ^b   Hamann, Philip R ^b   Gorovits, Boris ^b   Udata, Chandrasekhar ^b   Moran, Justin K ^b   Popplewell, Andrew G ^b   Stephens, Sue ^b   Frost, Philip ^b   Damle, Nitin K ^a  

^a WYETH RESEARCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CALICHEAMICIN; CD22 ANTIGEN; CMC 544; GEMTUZUMAB OZOGAMICIN; IMMUNOGLOBULIN G4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD22; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER INHIBITION; CYTOTOXICITY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR REGRESSION; XENOGRAFT;

EID: 10744229449     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2466     Document Type: Article

References (36)

1. Trail P, Bianchi A. Monoclonal antibody drug conjugates in the treatment of cancer. Current Opin Immunol. 1999;11:584-588.
2. Dubowchik G, Walker M. Receptor-mediated and enzyme-dependent targeting of cytotoxic anti-cancer drugs. Pharmacol Ther. 1999;83:67-123.
3. Bross PF, Beitz J, Chen G, et al. Gemtuzumab azogamicin: approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490-1496.
4. Berger M, Leopold L, Dowell J, Korth-Bradley J, Sherman M. Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse. Invest New Drugs. 2002;20:395-406.
5. Sievers E, Larson R, Stadmauer E, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244-3254.
6. Larson R, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002;16:1627-1636.
7. Hamann P, Hinman L, Beyer C, et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Biocon. Chem. 2002;3:40-46.
8. Hamann P, Hinman L, Hollander I, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconj Chem. 2002;13:47-58.
9. Lee M, Dunne T, Chang C, et al. Calicheamicins, a novel family of antibiotics. 4: structural elucidations of calicheamicins. J Am Chem Soc. 1992;114:985-987.
10. Zein N, Sinha A, McGahren W, Ellestad G. Calicheamicin γI: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science. 1988;240:1198-1201.
11. Thorson J, Sievers E, Ahlert J, et al. Understanding and exploiting Nature's chemical arsenal: the past, present and future of calicheamicin research. Current Pharm Des. 2000;6:1841-1879.
12. FDA. Mylotarg label. Available at: http://www.fda. gov/cder/foi/label/2000/21174lbl.pdf. Accessed on June 1, 2003.
13. Andrews R, Singer J, Bernstein I. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med. 1989;169:1721-1731.
14. Kreitman RJ. Toxin-labeled monoclonal antibodies. Curr Pharm Biotechnol. 2001;2:313-325.
15. Pastan I, Kreitman RJ. Immunotoxins in cancer therapy. Curr Opin Investig Drugs. 2002;3:1089-1091.
16. Kreitman RJ. Recombinant toxins for the treatment of cancer. Curr Opin Mol Ther. 2003;5:44-51.
17. Crocker PR, Varki A. Siglecs, sialic acids and innate immunity. Trends Immunol. 2001;22:337-342.
18. Hursey M, Newton DL, Hansen HJ, Ruby D, Goldenberg DM, Rybak SM. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics. Leuk Lymphoma. 2002;43:953-959.
19. Nitschke L, Floyd H, Crocker PR. New functions for the sialic acid-binding adhesion molecule CD22, a member of the growing family of Siglecs. Scand J Immunol. 2001;53:227-234.
20. Moyron-Quiroz JE, Partida-Sanchez S, Donis-Hernandez R, Sandoval-Montes C, Santos-Argumedo L. Expression and function of CD22, a B-cell restricted molecule. Scand J Immunol. 2002;55:343-351.
21. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol. 1997;15:481-504.
22. Hanna R, Ong GL, Mattes MJ. Processing of antibodies bound to B-cell lymphomas and other hematological malignancies. Cancer Res. 1996;56:3062-3068.
23. Shan D, Press OW. Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol. 1995;154:4466-4475.
24. Adair JR, Athwal DS, Emtage JS. Humanised antibodies. International Patent Publication 1991; WO91 / 09967.
25. Genentech. Rituxan label. Available at: http://www.rituxan.com/rituxan/pi.htm. Accessed on June 1, 2003.
26. BIAevaluation version 3.0. Software Handbook. Uppsala, Sweden: BIAcore; 1997.
27. Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol. 2001;41:1206-1214.
28. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York, NY: Marcel-Dekker; 1982.
29. French R, Powers U. Estimation of AUC and its variance in animal pharmacokinetic studies with partial concentration-time profiles. Wyeth-Ayerst Biometdcs Report 96031. 1996;1-12.
30. Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 1993;53:3336-3342.
31. Damle NK, Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr Opin Pharmacol. 2003;3:386-390.
32. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345:241-247.
33. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443-446.
34. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin's lymphomas. Blood. 2003;101:949-954.
35. Leonard JP, Link BK. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin Oncol. 2002;19:81-86.
36. Schindler J, Sausville E, Messmann R, Uhr JW, Vitetta ES. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Clin Cancer Res. 2001;7:255-258.